Kenvue
KVUE
$17.73
+1.14%
Kenvue Inc. is the world's largest pure-play consumer health company, operating across three core segments — Self Care (Tylenol, Listerine, Zyrtec), Essential Health (Johnson's, Band-Aid, Aveeno), and Skin Health and Beauty (Neutrogena, Dr. Teal's) — with over $15 billion in annual revenue and approximately 22,000 employees. Spun off from Johnson & Johnson's consumer segment and publicly listed in May 2023, the company holds a portfolio of iconic, category-leading brands that give it significant shelf-space leverage and pricing power in the household and personal products industry. The dominant investor narrative today centers on the announced acquisition by Kimberly-Clark, a deal signed in November 2025 and expected to close in the second half of 2026, which has effectively capped KVUE's independent equity story and shifted focus to merger-arbitrage dynamics, integration risk, and regulatory approval milestones. Recent news flow underscores this theme, with Zacks highlighting that the deal is nearing closing but warning of integration risks and near-term volatility, while earlier 2026 coverage noted earnings beats and analyst repositioning around the transaction.…
KVUE
Kenvue
$17.73
Related headlines
Investment Opinion: Should I buy KVUE Today?
The synthesized recommendation is Hold. The core thesis is that KVUE offers a solid 4.80% dividend yield and a deep forward PE discount at 13.87x, but the pending Kimberly-Clark acquisition creates significant uncertainty that caps near-term upside. The analyst consensus is uniformly Neutral/Equal Weight/Hold with an average target price of $19.50, implying 13.4% upside, which is moderate but not compelling enough to justify a Buy rating given the risks.
Supporting evidence includes: 1) Forward PE of 13.87x versus trailing PE of 22.32x, a 37.9% compression suggesting undervaluation; 2) Revenue growth of 3.02% year-over-year in Q2 2026, which is modest but stable; 3) Net margin improvement from 8.73% in Q4 2025 to 11.53% in Q2 2026, showing operational efficiency; 4) Free cash flow yield of approximately 6.4%, comfortably covering the dividend; and 5) Implied upside of 13.4% to the average analyst target of $19.50. Compared to the broader consumer staples sector, where large-cap names trade at 18x-25x trailing PE, KVUE's 22.32x is mid-range, but its forward PE is at a discount.
The biggest risks that could invalidate the thesis are: 1) Deal failure or renegotiation, which could cause a sharp decline toward the 52-week low of $14.02; 2) Integration risks post-merger, as highlighted by Zacks, potentially leading to earnings volatility; and 3) Weak revenue growth of 3.02% failing to accelerate, limiting multiple expansion. The rating would upgrade to Buy if the forward PE compresses below 12x or if revenue growth accelerates above 5%, and downgrade to Sell if the deal fails or if free cash flow declines below $1.5 billion. Relative to its history, the stock is undervalued on a forward basis but fairly valued on trailing metrics; relative to peers, it is fairly valued to slightly undervalued. Overall, the stock is fairly valued with a slight undervaluation on forward earnings, but the merger overhang warrants a Hold.
Sign up to view all
KVUE 12-Month Price Forecast
KVUE presents a balanced risk/reward profile with a neutral stance. The deep forward PE discount and solid free cash flow yield of 6.4% are attractive, but the pending Kimberly-Clark acquisition caps upside and introduces event risk. The stock's recent underperformance (-10.09% in one month) reflects deal uncertainty, and the low beta of 0.426 provides downside cushion but not immunity to deal failure. The base case (55% probability) assumes the deal closes on current terms, targeting $18-$20. An upgrade to bullish would require deal closure with strong synergies or revenue acceleration above 5%; a downgrade to bearish would occur if the deal fails or free cash flow deteriorates below $1.5 billion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.50 and implied upside of +10.0% versus the current price.
Average Target
$19.50
0 analysts
Implied Upside
+10.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Kenvue is covered by 12 analysts, with a consensus recommendation that is notably cautious — the recommendation field returns "none," and the institutional ratings data shows a uniform pattern of Neutral, Equal Weight, and Hold ratings from UBS, Barclays, Citigroup, and Canaccord Genuity across multiple dates in 2026, with no upgrades or downgrades, indicating a stable but unenthusiastic stance. The average target price is $19.50, which against the current price of $17.20 implies upside of approximately +13.4%, suggesting analysts see moderate value but not a compelling re-rating opportunity. The consensus leans neutral-to-mildly-bullish, with the target range spanning from a low of $18.00 to a high of $23.00 — a spread of $5.00, or roughly 29% of the current price, which signals meaningful uncertainty about the company's trajectory, likely tied to the pending Kimberly-Clark acquisition and its integration outcomes. The high target of $23.00 implies approximately +33.7% upside and would require either a sweetened deal price, successful integration with Kimberly-Clark driving multiple expansion, or a significant acceleration in organic growth and margin expansion beyond current trends. The low target of $18.00 implies just +4.7% upside and appears to price in a scenario where the deal closes at or near current terms with limited synergies, or where competitive pressures and input cost inflation compress margins. The tight clustering of institutional ratings around Neutral/Equal Weight/Hold — with no Buy ratings visible in the recent ratings history — suggests that analysts are in a wait-and-see mode, unwilling to upgrade until deal terms are finalized or until there is clearer visibility into post-merger earnings power; this uniform neutrality, combined with the relatively narrow target range, indicates moderate conviction but also limited downside protection if deal sentiment sours.
Bulls vs Bears: KVUE Investment Factors
The bear case currently holds stronger evidence due to the merger overhang, weak revenue growth, and severe recent underperformance, though the bull case is supported by deep forward valuation and solid cash flow. The most important tension is whether the Kimberly-Clark deal closes on current terms or faces delays/ren egotiation, which would significantly alter the investment thesis. If the deal closes smoothly, the forward PE of 13.87x and 6.4% FCF yield could drive a re-rating; if integration risks materialize, the stock could retest its 52-week low of $14.02. The low beta of 0.426 provides some downside protection, but the event risk from the merger is not captured by beta. Overall, the risk/reward is balanced but skewed slightly bearish until deal clarity emerges.
Bullish
- Deep Forward PE Discount: KVUE trades at a forward PE of 13.87x versus a trailing PE of 22.32x, a 37.9% compression that implies the market expects substantial earnings growth. The PEG ratio of 0.524 is well below 1.0, signaling undervaluation relative to expected growth.
- Solid Free Cash Flow Yield: Trailing twelve-month free cash flow of $2.117 billion against a market cap of $32.95 billion yields approximately 6.4%, comfortably covering the 4.80% dividend. Q2 2026 free cash flow was $826.8 million, demonstrating robust cash generation.
- Improving Profitability Trend: Net margin expanded from 8.73% in Q4 2025 to 12.13% in Q1 2026 and 11.53% in Q2 2026, driven by gross margin stability at 58.18% and operating leverage. Operating margin reached 17.67% in Q2 2026.
- Analyst Target Upside: The average analyst target price of $19.50 implies 13.4% upside from the current $17.20, with a high target of $23.00 suggesting 33.7% potential. The low target of $18.00 still offers 4.7% upside.
Bearish
- Merger Overhang Caps Upside: The pending Kimberly-Clark acquisition, signed in November 2025 and expected to close in H2 2026, has effectively capped KVUE's independent equity story. Recent news highlights integration risks and near-term volatility, limiting re-rating potential.
- Weak Revenue Growth: Q2 2026 revenue grew just 3.02% year-over-year to $3.955 billion, consistent with a mature consumer health business. No single high-growth segment exists to accelerate the trajectory, limiting organic re-rating potential.
- Recent Severe Underperformance: KVUE has declined 10.09% over the past month and 13.26% over three months, massively underperforming the S&P 500's 0.59% and 3.34% gains respectively. Relative strength versus SPY is -10.68% for one month.
- Stretched Balance Sheet Metrics: The current ratio of 0.958 is below 1.0, indicating current liabilities marginally exceed current assets. The payout ratio of 107.55% suggests dividends exceed GAAP earnings, relying on free cash flow to fund distributions.
KVUE Technical Analysis
Kenvue is in a range-bound consolidation phase with a mild upward bias over the trailing year, posting a 1-year price change of +9.35% while sitting at a current price of $17.20 against a 52-week range of $14.02 to $20.13 — placing it at roughly 52% of its 52-week range, squarely in the middle of the band. This mid-range positioning signals neither momentum-driven overextension nor deep-value distress, but rather a stock that has been oscillating around a fair-value zone as the market digests the pending Kimberly-Clark acquisition. The 6-month change of +0.35% confirms that the intermediate trend has essentially flatlined, with the stock having round-tripped from its mid-year highs back toward the middle of its range. Recent momentum has deteriorated sharply: the 1-month change of -10.09% and 3-month change of -13.26% reveal a pronounced deceleration that diverges from the positive 1-year trend, suggesting the stock is undergoing a corrective pullback after peaking near $19.83 in early July 2026. This divergence — positive long-term, negative short-term — is characteristic of a stock that rallied on deal optimism and is now retracing as merger-arbitrage spreads tighten and deal-completion uncertainty weighs on sentiment; notably, KVUE's 1-month relative strength versus SPY is -10.68%, indicating severe underperformance against a market that gained 0.59% over the same period. Key technical levels are well-defined: the 52-week low at $14.02 serves as the ultimate support zone, while the 52-week high at $20.13 represents the ceiling that has capped every rally attempt; a breakout above $20.13 would signal renewed conviction in deal completion or a sweetened offer, while a breakdown below $17.00 (the recent consolidation floor) could open the door toward the $14-$15 support band. With a beta of just 0.426, KVUE is roughly 57% less volatile than the broader market, which is typical for a consumer staples name but also reflects the dampening effect of a pending acquisition that has compressed idiosyncratic price swings; this low beta means position sizing can be larger for equivalent risk budgets, though the deal overhang introduces event risk that beta does not capture.
Beta
0.45
0.45x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$14-$20
Price range past year
Annual Return
+10.3%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | +1.0% |
| 3m | -9.0% | +2.5% |
| 6m | +2.2% | +13.9% |
| 1y | +10.3% | +15.0% |
| ytd | +2.4% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Kenvue's revenue trajectory is modestly positive but uninspiring for a consumer staples leader, with the most recent quarter (Q2 2026, ended June 28, 2026) delivering $3.955 billion in revenue and a year-over-year growth rate of just 3.02%. Tracing the multi-quarter trend, revenue has moved from $3.662 billion in Q4 2024 to $3.741 billion in Q1 2025, $3.839 billion in Q2 2025, $3.764 billion in Q3 2025, $3.780 billion in Q4 2025, $3.909 billion in Q1 2026, and $3.955 billion in Q2 2026 — a slow, steady climb that implies roughly 3-4% annualized growth, consistent with a mature consumer health business. Segment data shows Self Care as the largest contributor at $1.589 billion, followed by Essential Health at $1.253 billion and Skin Health and Beauty at $1.113 billion; the balanced mix provides diversification but also means no single high-growth segment is available to accelerate the overall trajectory, which limits the organic re-rating potential absent the Kimberly-Clark deal. Profitability is solid and improving: Q2 2026 net income was $456 million on $3.955 billion in revenue, yielding a net margin of 11.53%, while gross margin stood at 58.18% and operating margin at 17.67%. Comparing across recent quarters, net income has risen from $330 million in Q4 2025 to $474 million in Q1 2026 and $456 million in Q2 2026, with net margin expanding from 8.73% in Q4 2025 to 12.13% in Q1 2026 and 11.53% in Q2 2026 — a clear improvement driven by gross margin stability (58.18% in Q2 2026 vs. 56.53% in Q4 2025) and operating leverage. The gross margin of 58.18% is healthy for the household and personal products industry, where mid-to-high 50s is typical for branded consumer health players, and the operating margin of 17.67% reflects the company's ability to manage SG&A effectively despite significant brand investment. The balance sheet and cash flow profile is adequate but not fortress-like: debt-to-equity stands at 0.79, the current ratio is 0.958 (slightly below 1.0, indicating current liabilities marginally exceed current assets), and ROE is a respectable 13.66% while ROA is 6.99%. Free cash flow on a trailing twelve-month basis is $2.117 billion, which against a market cap of approximately $32.95 billion implies an FCF yield of roughly 6.4% — a solid cash generation profile that comfortably covers the dividend, though the payout ratio of 107.55% (based on EPS of $0.0446, which appears distorted by one-time items) and dividend yield of 4.80% suggest the company is returning more cash than its GAAP earnings support, relying on its robust FCF to fund distributions. The Q2 2026 cash flow statement shows $688 million in operating cash flow and $826.8 million in free cash flow, with $398 million returned via dividends, indicating that internal cash generation is sufficient to fund both growth capex ($138.8 million) and shareholder returns without external financing dependence.
Quarterly Revenue
$4.0B
2026-06
Revenue YoY Growth
+3.0%
YoY Comparison
Gross Margin
58.2%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Because Kenvue is profitable — with trailing net income positive and Q2 2026 net income of $456 million — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 22.32x and a forward PE of 13.87x, a dramatic 37.9% compression that implies the market expects significant earnings growth ahead, likely driven by margin expansion, cost synergies, or the earnings accretion anticipated from the Kimberly-Clark combination. The PEG ratio of 0.524 further supports the view that the stock is undervalued relative to its expected growth rate, as a PEG below 1.0 typically signals that the market is not fully pricing in future earnings expansion. On a peer-comparison basis, the valuation data does not provide a direct industry average PE, but context can be drawn from the broader consumer staples sector, where large-cap names typically trade in the 18x-25x trailing PE range; KVUE's 22.32x trailing PE sits in the middle of that band, while its forward PE of 13.87x represents a meaningful discount to sector norms, suggesting the market is pricing in deal-related uncertainty or integration risk. The PS ratio of 2.18x and EV/EBITDA of 13.77x are reasonable for a branded consumer health company with 58% gross margins, though the PB ratio of 3.06x is on the higher side and reflects the company's relatively asset-light brand portfolio. Historically, KVUE's PE ratio has ranged from a low of 17.24x (Q1 2026) to a high of 148.10x (Q2 2024, distorted by a near-zero earnings quarter), with more representative readings clustering in the 19x-35x range during 2024-2025; the current 22.32x trailing PE is near the lower end of that historical band, suggesting the stock is trading at a discount to its own recent valuation history. The PS ratio of 2.18x is also well below the 8x-12x range seen throughout 2024 and early 2025, though this comparison is complicated by the fact that the historical ratios data appears to use different share count or revenue bases; on a consistent basis, the current valuation appears undemanding, with the forward PE of 13.87x implying that if earnings materialize as expected, the stock is priced for a re-rating.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. The current ratio of 0.958 is below 1.0, indicating current liabilities marginally exceed current assets, which could strain liquidity if cash flows deteriorate. The payout ratio of 107.55% means dividends exceed GAAP earnings, relying on free cash flow of $2.117 billion to fund distributions; any cash flow disruption could jeopardize the dividend. Revenue growth of just 3.02% year-over-year in Q2 2026 is slow, and with no high-growth segment, the company lacks an internal catalyst to accelerate growth. Additionally, debt-to-equity of 0.79 is manageable but not fortress-like, and interest expense of $90 million in Q2 2026 consumes a portion of operating income.
Market and competitive risks are elevated due to the pending Kimberly-Clark acquisition. The deal has capped KVUE's independent equity story, and recent news from Zacks highlights integration risks and near-term volatility. The stock has underperformed the S&P 500 by 10.68% over the past month and 16.60% over three months, reflecting deal-related uncertainty. With a beta of 0.426, KVUE is less sensitive to market swings, but sector rotation risk remains if consumer staples fall out of favor. Competitive pressures in consumer health are intense, and KVUE's brands, while iconic, face challenges from private labels and changing consumer preferences. The uniform Neutral/Equal Weight/Hold ratings from 12 analysts suggest limited conviction and potential for downgrades if deal terms worsen.
Worst-case scenario: If the Kimberly-Clark deal fails to close or is renegotiated at a lower price, KVUE could retest its 52-week low of $14.02, representing a 18.5% decline from the current $17.20. The analyst low target of $18.00 is above the current price, but in a failed-deal scenario, the stock could fall below that. Historical max drawdown is -32.1%, indicating that in a severe adverse scenario, the stock could lose over 30% from its peak. From the current price, a drop to $14.02 would mean a loss of approximately 18.5%, and if the stock revisits its max drawdown level, losses could exceed 30%. This risk is compounded by the low current ratio and high payout ratio, which could force dividend cuts if cash flows weaken.
FAQ
The key risks include: 1) Merger risk: the Kimberly-Clark deal could fail or be renegotiated, potentially driving the stock to its 52-week low of $14.02, an 18.5% decline. 2) Financial risk: the current ratio of 0.958 is below 1.0, and the payout ratio of 107.55% exceeds GAAP earnings, relying on free cash flow to sustain dividends. 3) Competitive risk: slow revenue growth of 3.02% year-over-year and no high-growth segment limit upside. 4) Market risk: the stock has underperformed the S&P 500 by 16.60% over three months, and sector rotation could further pressure the shares. Ranked by severity, merger risk is highest, followed by financial and competitive risks.
The 12-month forecast includes three scenarios: bull case (25% probability) targeting $21-$23 if the deal closes with strong synergies; base case (55% probability) targeting $18-$20 if the deal closes on current terms; and bear case (20% probability) targeting $14-$16 if the deal fails or is renegotiated. The base case is most likely, assuming the acquisition completes in H2 2026 without major disruptions and revenue growth remains around 3%. The analyst average target of $19.50 aligns with the base case. Key assumptions include stable net margins above 11% and no regulatory hurdles. The stock's low beta of 0.426 suggests limited volatility, but deal news could cause sharp moves.
KVUE appears undervalued on a forward basis, with a forward PE of 13.87x versus a trailing PE of 22.32x, a 37.9% compression that implies expected earnings growth. The PEG ratio of 0.524 is well below 1.0, typically signaling undervaluation. However, the PS ratio of 2.18x and EV/EBITDA of 13.77x are reasonable for a consumer health company with 58% gross margins. Compared to the broader consumer staples sector, where large caps trade at 18x-25x trailing PE, KVUE's 22.32x is mid-range, but its forward PE is at a discount. The market is pricing in deal-related uncertainty; if the acquisition closes smoothly, the stock could re-rate toward the analyst average target of $19.50. Relative to its own history, the current PE is near the lower end of its 19x-35x range from 2024-2025.
KVUE may be a good buy for income-focused investors seeking a 4.80% dividend yield and a forward PE of 13.87x, which is a 37.9% discount to its trailing PE. The average analyst target of $19.50 implies 13.4% upside, but the pending Kimberly-Clark acquisition introduces significant event risk. The stock has underperformed the S&P 500 by 10.68% over the past month, reflecting deal uncertainty. For risk-averse investors, the low beta of 0.426 and solid free cash flow yield of 6.4% provide some comfort. However, the uniform Neutral ratings from 12 analysts suggest limited near-term catalysts. It is a good buy only if you are comfortable with merger-arbitrage dynamics and can tolerate potential downside to $14.02 if the deal fails.
KVUE is more suitable for short-to-medium-term investment (6-12 months) focused on the Kimberly-Clark acquisition catalyst, rather than long-term holding. The company is in a mature growth stage with 3.02% revenue growth, and its dividend yield of 4.80% appeals to income investors, but the payout ratio of 107.55% raises sustainability concerns. The beta of 0.426 indicates low volatility, making it less ideal for short-term trading, but the merger event could create price dislocations. Earnings visibility is moderate, with analysts uniformly Neutral. A suggested minimum holding period is until the deal closes in H2 2026, after which investors should reassess based on integration progress and post-merger financials. For long-term investors, waiting for deal clarity is prudent.